Rapid Fire: Engineered Microenvironments to Model Disease

Timeslot: Wednesday, April 11, 2018 - 3:15pm to 4:45pm
Track: Wound Healing and Cellular Microenvironment
Room: 208/209

About

Biomaterials have been invaluable tools for understanding how cells respond to their microenvironment in both health and disease. Here, we invite contributions that develop biomaterial platforms for cell culture or tissue engineering. Session topics include the following: understanding of the mechanisms that determine cellular responses to disease/injury, determining how biophysical and biochemical cues alter cellular behavior in 3D, identifying differences between 2D and 3D microenvironments in mediating cellular phenotype or response to treatment, developing complex tissue microstructures/organioids, culturing multiple types of cells within complex microenvironments, driving or enriching specific populations, developing improved approaches for utilization of patient derived or difficult to culture cells, drug screening within engineered microenvironments, and engineering microenvironments for therapeutic purposes.

Abstracts

  • Musculoskeletal Disease

  • 3:15 p.m. 153. WITHDRAWN

  • 3:20 p.m. 154. A 3D in vitro Osteoarthritis Model to Evaluate the Therapeutic Potential of Human Mesenchymal Stem Cells, P Diaz-Rodriguez*, H Chen, S Samavedi, M Hahn; Rensselaer Polytechnic Institute, Troy, NY

  • 3:25 p.m. 155. The Role of Mechanotransduction on Myoblasts in Muscle Injury Using Dynamically Stiffening Polymers, J. Silver*(1), T. Brown(1), T. Vogler(1), F. DelRio(2), A. Mckay(1), B. Olwin(1), K. Anseth(1); (1)University of Colorado, Boulder, Boulder, CO, (2)National Institute of Standards and Technology, Boulder, CO

  • 3:30 p.m. 156. Mimicking Paracrine Signals between Macrophages and Fibroblasts in a 3D Wound Healing Model in vitro, F. Ullm, M. Ansorge, J. Sapudom, K. Franke, T. Pompe*; University of Leipzig, Leipzig, Germany

  • 3:35 p.m. 157. Engineering of an In Vitro Model of Discogenic Low Back Pain, S. Romereim*, E. Johnson, R. Wachs; University of Nebraska-Lincoln, Lincoln, NE

  • Cancer

  • 3:45 p.m. 158. Mechanobiologically-modulated microniches for investigation of angiogenesis induced liver fibrosis and drug testing, L. Liu*; Tsinghua University, Beijing, China

  • 3:50 p.m. 159. Matrix Adhesivity and Stiffness Regulate Metastatic Breast Cancer Dormancy, S. Pradhan*, M. Chatterjee, J. Slater; University of Delaware, Newark, DE

  • 3:55 p.m. 160. Fibrous topography promotes cell spreading and migration in 3D, D Matera*, B Baker; University of Michigan, ann arbor, MI

  • 4:00 p.m. 161. Synthetic Hydrogels with Highly Bioactive Basement Membrane Functionality, R. Wilson*, G. Swaminathan, K. Grande-Allen; Rice University, Houston, TX

  • 4:05 p.m. 162. Decoupling the Impact of Hydrogel Stiffness and Mesh Size for Studying Matrix Metalloproteinase-Mediated Behavior of Metastatic Breast Cancer Cells, A. Narkhede*, S. Rao; The University of Alabama, Tuscaloosa, AL

  • 4:15 p.m. 163. Biomaterials Models of Glioblastoma Microenvironment, W Xiao, A Sohrabi, Y Ghochani, A Ehsanipour, R Zhang, S Sun, L Ta, H Kornblum, D Nathanson, S Seidlits*; University of California Los Angeles, Los Angeles, CA

  • 4:20 p.m. 164. Polymer Scaffolds for Early Detection and Vaccination Against Metastatic Breast Cancer, Y. Zhang*, K. Hughes, R. Oakes, G. Bushnell, R. Hartfield, M. Cascalho, J. Platt, J. Jeruss, L. Shea; University of Michigan, Ann Arbor, MI

  • 4:25 p.m. 165. In Vitro Bioengineered Prostate Tumor Model for Recapitulation of the Native Tumor Microenvironment, N. Habbit*(1), B. Anbiah(1), I. Hassani(1), M. Eggert(1), S. Jasper(1), B. Prabhakarpandian(2), R. Arnold(1), E. Lipke(1); (1)Auburn University, Auburn, AL, (2)CFD Research Corporation, Huntsville, AL

  • 4:30 p.m. 166. Three-Dimensional Engineered Tumor Tissues Using Patient-Derived Colorectal Cancer Xenografts, I Hassani*, B Anbiah, B Ahmed, N Habbit, M Greene, E Lipke; Auburn University, Auburn, AL

  • 4:35 p.m. 167. Effect of 3D Porous Chitosan-Alginate Scaffold Stiffness on Prostate Cancer Malignancy, K. Xu*(1), K. Ganapathy(1), T. Andl(1), Z. Wang(1), J. Copland(2), R. Chakrabarti(1), S. Florczyk(1); (1)University of Central Florida, Orlando, FL, (2)Mayo Clinic, Jacksonville, FL